These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16917204)

  • 1. Prevention of Alzheimer disease.
    Thal LJ
    Alzheimer Dis Assoc Disord; 2006; 20(3 Suppl 2):S97-9. PubMed ID: 16917204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary prevention trials in Alzheimer disease.
    Green RC; DeKosky ST
    Neurology; 2006 Nov; 67(9 Suppl 3):S2-5. PubMed ID: 17101930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention trials in Alzheimer disease: one step forward?
    Touchon J; Portet F; Gauthier S
    Neurology; 2006 Nov; 67(9 Suppl 3):S21-2. PubMed ID: 17101931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of Alzheimer's Disease: Lessons Learned and Applied.
    Galvin JE
    J Am Geriatr Soc; 2017 Oct; 65(10):2128-2133. PubMed ID: 28766695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug discovery and the prevention of Alzheimer's disease.
    Fillit H
    Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S26-8. PubMed ID: 18631996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADCS Prevention Instrument Project: overview and initial results.
    Ferris SH; Aisen PS; Cummings J; Galasko D; Salmon DP; Schneider L; Sano M; Whitehouse PJ; Edland S; Thal LJ;
    Alzheimer Dis Assoc Disord; 2006; 20(4 Suppl 3):S109-23. PubMed ID: 17135805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintaining adherence and retention in dementia prevention trials.
    DeKosky ST
    Neurology; 2006 Nov; 67(9 Suppl 3):S14-6. PubMed ID: 17101928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary prevention and delay of onset of AD/dementia.
    Feldman HH; Jacova C
    Can J Neurol Sci; 2007 Mar; 34 Suppl 1():S84-9. PubMed ID: 17469689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NIH state-of-the-science conference statement: Preventing Alzheimer's disease and cognitive decline.
    Daviglus ML; Bell CC; Berrettini W; Bowen PE; Connolly ES; Cox NJ; Dunbar-Jacob JM; Granieri EC; Hunt G; McGarry K; Patel D; Potosky AL; Sanders-Bush E; Silberberg D; Trevisan M
    NIH Consens State Sci Statements; 2010 Apr; 27(4):1-30. PubMed ID: 20445638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials.
    Vermunt L; Veal CD; Ter Meulen L; Chrysostomou C; van der Flier W; Frisoni GB; Guessous I; Kivipelto M; Marizzoni M; Martinez-Lage P; Molinuevo JL; Porteous D; Ritchie K; Scheltens P; Ousset PJ; Ritchie CW; Luscan G; Brookes AJ; Visser PJ
    Alzheimers Dement; 2018 Jun; 14(6):837-842. PubMed ID: 29604264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).
    Meinert CL; Breitner JC
    Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S7-S14. PubMed ID: 18632005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics.
    Coley N; Gallini A; Andrieu S
    CNS Drugs; 2015 Jul; 29(7):519-28. PubMed ID: 26188654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint.
    Vellas B; Andrieu S; Ousset PJ; Ouzid M; Mathiex-Fortunet H;
    Neurology; 2006 Nov; 67(9 Suppl 3):S6-11. PubMed ID: 17101932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential prevention strategies for Alzheimer disease.
    Thal LJ
    Alzheimer Dis Assoc Disord; 1996; 10 Suppl 1():6-8. PubMed ID: 8876780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives.
    Wang J; Tan L; Yu JT
    J Alzheimers Dis; 2016; 50(4):927-45. PubMed ID: 26836177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designing a large prevention trial: statistical issues.
    Kryscio RJ; Mendiondo MS; Schmitt FA; Markesbery WR
    Stat Med; 2004 Jan; 23(2):285-96. PubMed ID: 14716729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI).
    Walsh SP; Raman R; Jones KB; Aisen PS;
    Alzheimer Dis Assoc Disord; 2006; 20(4 Suppl 3):S170-8. PubMed ID: 17135810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADCS Prevention Instrument Project: pharmacoeconomics: assessing health-related resource use among healthy elderly.
    Sano M; Zhu CW; Whitehouse PJ; Edland S; Jin S; Ernstrom K; Thomas RG; Thal LJ; Ferris SH;
    Alzheimer Dis Assoc Disord; 2006; 20(4 Suppl 3):S191-202. PubMed ID: 17135812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward.
    Hsu D; Marshall GA
    Curr Alzheimer Res; 2017; 14(4):426-440. PubMed ID: 27697063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of hormone replacement therapy in the prevention of Alzheimer disease.
    Fillit HM
    Arch Intern Med; 2002 Sep; 162(17):1934-42. PubMed ID: 12230415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.